OBJECTIVE: Controversy exists over the significance of the isolated finding of cavum septi pellucidi (CSP) and its prevalence rate in healthy individuals and in professional boxers. Few magnetic resonance imaging (MRI) studies have looked at large cohorts of boxers. The aim of this study was to identify the prevalence and extent of a CSP among professional boxers and to compare these with a control group. METHODS: MRI studies of 164 male boxers scanned for annual British boxing board license renewal were reviewed and compared with 43 control patients. CSP prevalence, size, and extent were recorded. Extent was classified as type 1, anterior to the fornix; type 2, extending up to the fornix; and type 3, extending into the cavum vergae. Parenchymal abnormalities were documented, and the Evan's ratio was used as an indication of brain atrophy. RESULTS: A CSP was present in 40% of controls and 49% of boxers. There was a trend to a higher CSP prevalence in boxers (P = .099). No control patient had type 2 or 3 extension (P < .0009), as opposed to 30% and 16% prevalence in boxers. Three boxers increased their extent over serial imaging. No difference in CSP size was established between the 2 groups (P = .43), but there was an association between progressive scans and increased CSP size over time in boxers, independent of age (P = .05). Eight boxers demonstrated a CSP on a subsequent scan not seen on an earlier scan. CONCLUSION: The prevalence of a CSP is high among both control patients and boxers. There is a trend to a larger CSP with increasing number of scans without evidence of atrophy and independent of age. Boxers also have a greater posterior extent than controls. The findings may be explained by sudden increases in intracranial pressure that forced cerebrospinal fluid (CSF) through small defects in the septal leaflets, which result in an increase in size and or extent of a CSP. 2010 Canadian Association of Radiologists. Published by Elsevier Inc. All rights reserved.
OBJECTIVE: Controversy exists over the significance of the isolated finding of cavum septi pellucidi (CSP) and its prevalence rate in healthy individuals and in professional boxers. Few magnetic resonance imaging (MRI) studies have looked at large cohorts of boxers. The aim of this study was to identify the prevalence and extent of a CSP among professional boxers and to compare these with a control group. METHODS: MRI studies of 164 male boxers scanned for annual British boxing board license renewal were reviewed and compared with 43 control patients. CSP prevalence, size, and extent were recorded. Extent was classified as type 1, anterior to the fornix; type 2, extending up to the fornix; and type 3, extending into the cavum vergae. Parenchymal abnormalities were documented, and the Evan's ratio was used as an indication of brain atrophy. RESULTS: A CSP was present in 40% of controls and 49% of boxers. There was a trend to a higher CSP prevalence in boxers (P = .099). No control patient had type 2 or 3 extension (P < .0009), as opposed to 30% and 16% prevalence in boxers. Three boxers increased their extent over serial imaging. No difference in CSP size was established between the 2 groups (P = .43), but there was an association between progressive scans and increased CSP size over time in boxers, independent of age (P = .05). Eight boxers demonstrated a CSP on a subsequent scan not seen on an earlier scan. CONCLUSION: The prevalence of a CSP is high among both control patients and boxers. There is a trend to a larger CSP with increasing number of scans without evidence of atrophy and independent of age. Boxers also have a greater posterior extent than controls. The findings may be explained by sudden increases in intracranial pressure that forced cerebrospinal fluid (CSF) through small defects in the septal leaflets, which result in an increase in size and or extent of a CSP. 2010 Canadian Association of Radiologists. Published by Elsevier Inc. All rights reserved.
Authors: Inga K Koerte; Jakob Hufschmidt; Marc Muehlmann; Yorghos Tripodis; Julie M Stamm; Ofer Pasternak; Michelle Y Giwerc; Michael J Coleman; Christine M Baugh; Nathan G Fritts; Florian Heinen; Alexander Lin; Robert A Stern; Martha E Shenton Journal: J Neurotrauma Date: 2015-12-15 Impact factor: 5.269
Authors: Inga K Koerte; Alexander P Lin; Anna Willems; Marc Muehlmann; Jakob Hufschmidt; Michael J Coleman; Isobel Green; Huijun Liao; David F Tate; Elisabeth A Wilde; Ofer Pasternak; Sylvain Bouix; Yogesh Rathi; Erin D Bigler; Robert A Stern; Martha E Shenton Journal: Brain Pathol Date: 2015-05 Impact factor: 6.508
Authors: Dana Crooks; Nathaniel E Anderson; Matthew Widdows; Nia Petseva; Michael Koenigs; Charles Pluto; Kent A Kiehl Journal: Neuropsychologia Date: 2018-03-12 Impact factor: 3.139
Authors: Jaeuk Hwang; Jieun E Kim; Marc J Kaufman; Perry F Renshaw; Sujung Yoon; Deborah A Yurgelun-Todd; Yera Choi; Chansoo Jun; In Kyoon Lyoo Journal: PLoS One Date: 2013-10-24 Impact factor: 3.240
Authors: Sam Gandy; Milos D Ikonomovic; Effie Mitsis; Gregory Elder; Stephen T Ahlers; Jeffrey Barth; James R Stone; Steven T DeKosky Journal: Mol Neurodegener Date: 2014-09-17 Impact factor: 14.195
Authors: Peter Stanwell; Grant L Iverson; Ryan Van Patten; Rudolph J Castellani; Paul McCrory; Andrew J Gardner Journal: Front Neurol Date: 2022-04-06 Impact factor: 4.086